Identification of the specific muscarinic acetylcholine receptor (mAChR) subtypes mediating stimulation of salivary secretion is of considerable clinical interest. Recent pharmacological and molecular genetic studies have yielded somewhat confusing and partially contradictory results regarding the involvement of individual mAChRs in this activity. In the present study, we re-examined the roles of M 1 and M 3 mAChRs in muscarinic agonist-mediated stimulation of salivary secretion by using M 1 and M 3 receptor single-knockout (KO) mice and newly generated M 1 /M 3 receptor double-KO mice. When applied at a low dose (1 mg/kg, s.c.), the muscarinic agonist pilocarpine showed significantly reduced secretory activity in both M 1 and M 3 receptor single-KO mice. However, when applied at higher doses, pilocarpine induced only modestly reduced (5 mg/kg, s.c.) or unchanged (15 mg/kg, s.c.) salivation responses, respectively, in M 1 and M 3 receptor single-KO mice, indicating that the presence of either M 1 or M 3 receptors is sufficient to mediate robust salivary output. Quantitative reverse transcriptase-polymerase chain reaction studies with salivary gland tissue showed that the inactivation of the M 1 or M 3 mAChR genes did not lead to significantly altered mRNA levels of the remaining mAChR subtypes. Strikingly, the sialagogue activity of pilocarpine was abolished in M 1 /M 3 receptor double-KO mice. However, salivary glands from M 1 /M 3 receptor double-KO mice remained responsive to stimulation by the ␤-adrenergic receptor agonist, (S)-isoproterenol. Taken together these studies support the concept that a mixture of M 1 and M 3 receptors mediates cholinergic stimulation of salivary flow.
Saliva production and secretion are essential for maintaining the integrity of oral tissues, in speech, in protecting teeth from caries, and in the tasting and ingestion of food (Wiseman and Faulds, 1995) . Xerostomia (oral dryness) is caused by reduced salivary flow associated with malfunction of salivary glands. Xerostomia can occur in response to radiation therapy to the head and neck region and frequently accompanies diseases such as diabetes insipidus and cardiac failure, emotional states such as fear and depression, and autoimmune diseases such as Sjögren's syndrome (Wiseman and Faulds, 1995) . Moreover, a large number of drugs, including antidepressants, antihistamines, and antispasmodics, can cause xerostomia, primarily as a result of blockade of muscarinic receptors (Scully, 2003) .
The major salivary glands, the submandibular, sublingual, and parotid glands, are innervated by both parasympathetic and sympathetic nerves (Baum, 1993) . Activation of the parasympathetic fibers innervating the salivary glands leads to a copious flow of saliva, mediated by acetylcholine-induced activation of acinar cell muscarinic acetylcholine receptors (mAChRs) (Baum, 1993) . In fact, mAChR-mediated stimulation of saliva output is considered the major mechanism by which salivary fluid secretion is regulated physiologically (Baum, 1993; Turner and Sugiya, 2002; Scully, 2003) .
Stimulation of mAChRs located on salivary acinar cells is known to lead to the activation of G proteins of the G q family (Baum, 1993; Luo et al., 2001 ) which mediate an increase in intracellular calcium levels and the opening of calcium-activated Cl Ϫ and K ϩ channels (Baum, 1993; Turner and Sugiya, 2002) . Recent studies with gene knockout (KO) mice demonstrated that muscarinic agonist-induced salivary secretion is strongly reduced in mice lacking the aquaporin-5 water channel (Ma et al., 1999) or the Na ϩ /K ϩ /2Cl Ϫ cotransporter (Evans et al., 2000) , indicating that these two proteins represent key components of the signaling pathway stimulating salivary flow.
Identification of the specific mAChR subtype(s) mediating stimulation of salivary secretion is of considerable interest for the development of more selective muscarinic sialagogues or of drugs with reduced side effects. The mAChR family consists of five molecularly distinct members (M 1 -M 5 ) that can be subdivided, based on their G protein-coupling profiles, into two major functional subclasses (Caulfield, 1993; Wess, 1996; Caulfield and Birdsall, 1998) . Whereas the odd-numbered receptors (M 1 , M 3 , and M 5 ) are selectively coupled to G proteins of the G q family, the even-numbered mAChR subtypes (M 2 and M 4 ) are preferentially linked to G proteins of the G i class (Caulfield, 1993; Wess, 1996; Caulfield and Birdsall, 1998) .
Pharmacological, biochemical, and molecular genetic studies indicate that the M 3 receptor subtype plays a key role in mediating increased salivary flow (Laniyonu et al., 1990; Dai et al., 1991; Caulfield, 1993; Watson et al., 1996; Moriya et al., 1999; Matsui et al., 2000; Bockman et al., 2001; Bymaster et al., 2003) . However, pharmacological and biochemical studies suggest that M 1 (Watson and Culp, 1994; Culp et al., 1996; Luo et al., 2001; Tobin et al., 2002) and M 5 mAChRs (Flynn et al., 1997; Meloy et al., 2001; Tobin et al., 2002) may also play a role in muscarinic agonist-mediated salivary secretion. Moreover, two recent studies reported that muscarinic agonist-induced stimulation of salivary output was impaired not only in M 3 receptor KO mice but also in M 1 and M 4 receptor KO mice (Bymaster et al., 2003) and M 5 receptor KO mice . Taken together, these studies suggest that multiple mAChRs (M 1 , M 3 , M 4 , and M 5 ) may be involved in cholinergic stimulation of salivary flow.
To learn more about the functional roles of the M 1 and M 3 receptor subtypes as well as of non-M 1 /M 3 receptors in cholinergic stimulation of salivary secretion in vivo, we used M 1 and M 3 receptor single-KO mice and newly generated M 1 /M 3 receptor double-KO mice as novel experimental tools. All mutant mice and the corresponding WT controls received three different doses (1, 5, and 15 mg/kg, s.c.) of the nonselective muscarinic agonist pilocarpine, and the magnitudes of the resulting salivation responses were recorded. These studies were complemented by radioligand binding and quantitative reverse transcriptase (RT)-PCR studies (TaqMan), primarily to exclude the possibility that inactivation of one specific mAChR gene causes altered expression levels of the remaining mAChR subtypes.
Whereas high doses of pilocarpine led to robust salivary flow in M 1 and M 3 receptor single-KO mice, pilocarpineinduced salivary secretion was abolished in M 1 /M 3 receptor double-KO mice. This finding is consistent with the concept that mAChR-mediated stimulation of salivary secretion is mediated by a mixture of M 1 and M 3 receptors and that other glandular mAChRs are unlikely to contribute to this activity to a significant extent. These observations should be of considerable relevance for the design of more selective sialagogues or of muscarinic and nonmuscarinic drugs with reduced side effects on salivary flow.
Materials and Methods
Animals. The generation of homozygous M 1 and M 3 receptor KO mice (129SvEv [50%] ϫ CF1 [50%]) has been described previously Miyakawa et al., 2001; Fisahn et al., 2002) . To generate mice deficient in both M 1 and M 3 mAChRs, homozygous M 1 receptor KO mice were mated with homozygous M 3 receptor KO mice. The resulting F1 compound heterozygotes were then intercrossed to generate F2 offspring. According to Mendelian inheritance, 1/16 of the F2 pups would be expected to be homozygous for both the M 1 and the M 3 receptor gene disruptions (M 1 /M 3 receptor double-KO mice). M 1 /M 3 receptor double-KO mice were obtained at a frequency of about 4.7%, which is slightly below the predicted Mendelian frequency of 6.25%. The M 1 /M 3 receptor double-KO mice were interbred to generate mice used for the experiments described in this study. In parallel, the wild-type (WT) F2 mice were interbred to obtain WT control mice. Thus, both M 1 /M 3 receptor double-KO mice and the corresponding WT control mice had a genetic background that was identical to that of the M 1 and M 3 single-KO mice (129SvEv [50%] ϫ CF1 [50%]). The identity of the various mutant mouse strains was verified by Southern blotting and PCR analysis of mouse tail DNA as described previously Fisahn et al., 2002) .
The generation of M 2 /M 3 (Struckmann et al., 2003) and M 2 /M 4 All experiments were performed during the light cycle using adult male mice that were 10 to 18 weeks old. In all experiments, KO mice and age-matched WT mice of the same genetic background were run in parallel. All animal studies were conducted according to the National Institute of Diabetes and Digestive and Kidney Diseases guidelines for standard animal care and usage. Salivation Studies. For salivation studies, WT and mAChR mutant mice were anesthetized with pentobarbital (50 mg/kg, i.p.). Salivation responses to pilocarpine hydrochloride (1, 5, and 15 mg/ kg, s.c.) or (S)-isoproterenol bitartrate (1 mg/kg, s.c.) (both compounds were purchased from Sigma) were quantitated in 5-min intervals over a 35-min observation period by collecting saliva on filter paper using a method similar to that described by Parkes and Parks (1972) . In brief, mice were placed face down on a slightly inclined surface (about 5 o to the horizontal), with the heads facing downwards to allow free flow of saliva. After the injection of secretagogues, a preweighed piece of circular Whatman filter paper (diameter, 125 mm) was placed immediately below the mouth area of each mouse. Fresh pieces of preweighed filter paper were added in 5-min intervals (last change of filter paper was 30 min after injection of the secretagogue). Filter papers were weighed for the quantitation of saliva production.
Radioligand Binding Studies. Submandibular salivary glands were removed from individual mice and frozen immediately in liquid nitrogen. Tissue samples were homogenized for 30 s in 50 volumes of binding buffer (50 mM sodium phosphate buffer, pH 7.4, containing 2 mM MgCl 2 , and 100 mM NaCl) by using a Brinkmann homogenizer. The homogenates were then filtered through four layers of cheesecloth and centrifuged once at 50,000 ϫ g. The membrane pellets were resuspended in binding buffer at 60 mg/ml (tissue wet weight) and binding assays were carried out in triplicate according to a published method (Bymaster et al., 2003) . In brief, membrane homogenates (ϳ0.4 mg of protein/tube) were incubated in a 0.2-ml total volume of binding buffer for 2 h at room temperature (22°C molpharm.aspetjournals.org using the nonlinear curve-fitting program Prism 3.0 (GraphPad Software, San Diego, CA).
Nonspecific binding was determined in the presence of 10 M atropine. Bound and free ligand were separated by vacuum filtration over GF/B filters (Whatman, Clifton, NJ), pretreated with 0.3% polyethylenimine for 1 h. The filters were washed three times with 5 ml of ice-cold phosphate buffer, dried, and placed in vials with 7 ml of Bio-Safe II scintillation cocktail (Research Products International, Mt. Prospect, IL). Radioactivity bound to the filters was determined after 18 h of extraction.
Quantitative Real-Time PCR (TaqMan) Analysis of Salivary Gland cDNA from WT and mAChR Mutant Mice. Three age-matched WT, M 1 receptor KO, and M 3 receptor KO mice were sacrificed, and the sublingual and submandibular glands were excised and immediately snap frozen in liquid nitrogen. Total RNA was obtained from the individual gland tissues by homogenization in TRIzol (Invitrogen) according the manufacturer's instructions. The RNA preparations were further processed using the RNA cleanup protocol of the RNeasy Mini Kit (QIAGEN, Valencia, CA), including on-column DNase treatment using the RNase-free DNase set (QIAGEN), to obtain total RNA free of contaminating genomic DNA. RNA quantity and quality were assessed by measuring the absorbance at 260 and 280 nm using an Eppendorf Biophotometer (Eppendorf-5 Prime, Inc., Boulder, CO). Salivary gland RNA (1 g) was reverse-transcribed in a final volume of 100 l by using the highcapacity cDNA archive kit (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions.
Real-time PCR (TaqMan) was carried out on a 7900 HT sequence detection system (Applied Biosystems) using a 96-well format (final volume of reaction mixtures, 50 l). 18S rRNA (TaqMan RNA control reagents, VIC Probe; Applied Biosystems) was used as an internal standard for normalization of mAChR mRNAs in each reaction. Specific mouse M 1 -M 5 receptor primers and TaqMan probes (Table  1) were designed from GenBank sequences using Primer Express 1.0 software (Applied Biosystems) and were synthesized by Applied Biosystems. The subtype specificity of the primers/probes used was verified in control reactions using plasmid DNA containing the coding sequences of the mouse M 1 -M 5 mAChRs (data not shown). The amplification efficiencies of the individual primer-probe pairs were determined by serial dilution of cDNA and plotting of threshold cycle (C t ) values versus log input amount of cDNA. The amplification efficiencies of all primer-probe pairs were found to be between 1.9 and 2.0 (data not shown).
TaqMan reaction mixtures contained 5 l from the cDNA reaction (corresponding to 50 ng of total RNA), 1ϫ TaqMan universal master mix (Applied Biosystems), and all primers and probes at a final concentration of 200 nM. The following cycling conditions were used: 10 min at 95°C for activation of AmpliTaq Gold DNA polymerase, followed by 40 cycles of 15 s at 95°C for denaturation and 1 min at 60°C for annealing and amplification. Control reactions using RNA samples that had not been treated with RT were included as negative controls, confirming that the RNA samples were free of contaminating genomic DNA (data not shown). All RT reactions and TaqMan assays were carried out in duplicate. Relative mAChR expression levels were compared between samples from WT versus M 1 or M 3 receptor KO mice by comparing ⌬C t values (C t [mAChR] Ϫ C t [controlϭ18S rRNA]) (Livak and Schmittgen, 2001) .
Morphological Studies. Salivary glands were harvested from WT and M 1 /M 3 receptor double-KO mice. Tissues were fixed in 10% neutral buffered formalin, processed into paraffin blocks, sectioned at 6 m, and stained with hematoxylin and eosin. Stained sections were examined by light microscopy (BX41; Olympus, Tokyo, Japan). Photographs were taken with an Olympus DP12 digital camera, using the 20ϫ oil immersion lens.
Statistics. Statistical significance between two or more groups was determined by Student's t tests or one-way analysis of variance using post hoc t tests (Bonferroni's method).
Results
Dose-Dependence of the Sialagogue Activity of Pilocarpine in M 1 and M 3 Receptor Single-KO Mice. At first, we examined the ability of three different doses of pilocarpine (1, 5, and 15 mg/kg, s.c.) to stimulate salivary flow in M 1 and M 3 receptor single-KO mice (Fig. 1) . Administration of the lowest dose of pilocarpine (1 mg/kg) resulted in a significant reduction in saliva output in both M 1 and M 3 receptor single-KO mice, compared with the corresponding WT control mice. The reduction in the magnitude of salivary secretion was clearly more pronounced in the M 3 receptor KO than in the M 1 receptor KO mice (reduction in saliva output by ϳ90 and ϳ50%, respectively, measured over the entire 35 min observation period; Fig. 1A ).
In contrast, administration of the intermediate pilocarpine dose (5 mg/kg) produced only a rather modest reduction in salivary flow in the M 1 and M 3 receptor single-KO mice (reduction in saliva output by ϳ20% measured over the entire 35-min observation period; Fig. 1B ). This decrease proved to be statistically significant only in the case of the M 3 receptor KO mice (Fig. 1B) . Finally, the highest pilocarpine dose used (15 mg/kg) induced robust salivation responses in both M 1 and M 3 receptor single-KO mice that did not differ significantly from the corresponding WT responses (Fig. 1C) . Analysis of mAChR Gene Expression in Mouse Salivary Glands by Quantitative Real-Time PCR (TaqMan). As described in the previous paragraph, pilocarpine (5 and 15 mg/kg) retained the ability to mediate robust salivation responses in M 1 and M 3 receptor single-KO mice (Fig. 1) . To exclude the possibility that the robustness of these responses was caused by altered mAChR gene expression patterns (e.g. (Livak and Schmittgen, 2001) .
Quantitative real-time PCR analysis of cDNA prepared from mouse submandibular glands indicated that M 1 receptor transcripts were present at similar levels in WT and M 3 receptor KO mice (Fig. 2) . Likewise, M 3 receptor transcripts were expressed at similar levels in WT and M 1 receptor KO mice (Fig. 2) . In addition, TaqMan analysis showed that submandibular gland tissue from WT mice also contained low levels of M 2 , M 4 , and M 5 receptor mRNA (note the significant increase in ⌬C t values compared with the corresponding M 1 and M 3 receptor values). The relative mRNA expression levels of the M 2 , M 4 , and M 5 receptors remained unaffected by the lack of M 1 or M 3 receptors (Fig. 2) . Very similar results were obtained using cDNA prepared from sublingual gland tissue from WT and M 1 and M 3 receptor KO mice (data not shown). Taken together, these data indicate that inactivation of the M 1 or M 3 mAChR genes does not result in significantly altered mRNA levels of the remaining mAChRs expressed in salivary gland tissue.
Generation of M 1 /M 3 mAChR Double-KO Mice. To test the hypothesis that pilocarpine-induced salivary secretion is mediated by a mixture of M 1 and M 3 mAChRs, we generated M 1 /M 3 receptor double-KO mice as novel experimental tools (for experimental details, see Materials and Methods). The M 1 /M 3 receptor double-KO mice were fertile, seemed healthy, and showed no obvious behavioral abnormalities. However, like the M 3 receptor single-KO mice , adult M 1 /M 3 receptor double-KO mice weighed significantly less (ϳ30-40%) than the corresponding WT control mice. We also noted that intermating of male and female M 1 /M 3 receptor double-KO mice resulted in somewhat reduced litter sizes (average number of pups per litter: WT, 8.4 Ϯ 0.9; M 1 /M 3 double KO, 5.4 Ϯ 0.7; n ϭ 14). The reason underlying this phenomenon remains unclear at present.
Pilocarpine-Induced Salivary Secretion Is Abolished in M 1 /M 3 Receptor Double-KO Mice. We next tested the ability of pilocarpine (1, 5, and 15 mg/kg, s.c.) to stimulate salivary outflow in M 1 /M 3 receptor double KO and their corresponding WT control mice. These studies showed that pilocarpine-mediated salivary secretion was essentially abolished in M 1 /M 3 receptor double-KO mice (Fig. 3) , independent of the pilocarpine dose used. However, (S)-isoproterenol (1 mg/kg, s.c.) , an agent that stimulates salivary output via activation of ␤-adrenergic receptors, retained its stimulatory effect on saliva production in M 1 /M 3 receptor double-KO mice (Fig. 4) , indicating that the absence of both M 1 and M 3 mAChRs did not interfere with the integrity of downstream signal transduction cascades triggering salivary secretion. In fact, (S)-isoproterenol-mediated saliva outflow was even slighter higher in M 1 /M 3 receptor double-KO mice than in WT mice at several time points (p Ͻ 0.05; Fig. 4) .
In addition, light microscopic studies showed that the morphology of submandibular, sublingual, and parotid salivary glands from M 1 /M 3 receptor double-KO mice did not differ from that of the corresponding WT control mice (Fig. 5) .
[ (Fig. 6) .
Saturation binding studies with membranes prepared from submandibular glands from WT mice showed that [ 3 H]NMS bound to submandibular gland mAChRs with a K D of 0.357 Ϯ 0.007 nM (n ϭ 3). The [ 3 H]NMS concentration of 3 nM used for the studies described above therefore labels about 90% of the total mAChR population.
Pilocarpine-Induced Salivation in M 1 /M 4 , M 2 /M 3 , and M 2 /M 4 Receptor Double-KO Mice. Besides the M 1 /M 3 receptor double-KO mice described in detail above, we recently also generated M 2 /M 3 (Struckmann et al., 2003) , M 2 /M 4 (Dut- 
Discussion
Muscarinic antagonists are used clinically in many pathophysiological conditions including, for example, the treatment of Parkinson's disease and the reduction of increased bronchial, gastrointestinal, and bladder smooth muscle tone (Eglen et al., 1999; Wess, 2001) . A major side effect of these drugs is impaired salivary flow (dry mouth), predicted to be caused by blockade of glandular mAChRs. Impaired salivary flow is also a frequent side effect of many other classes of drugs including the tricyclic antidepressants, antipsychotics, ␤-adrenergic receptor blockers, and antihistaminergic drugs (Scully, 2003) . Muscarinic agonists such as pilocarpine are successfully used in the treatment of xerostomia (Wiseman and Faulds, 1995; Fox et al., 2001 ). Thus, determination of the specific mAChR subtypes involved in mediating enhanced salivary flow is of considerable therapeutic interest.
To learn more about the functional roles of the M 1 and M 3 mAChR subtypes in muscarinic agonist-induced salivary secretion in vivo, we used M 1 and M 3 receptor single-KO mice and newly generated M 1 /M 3 receptor double-KO mice as novel experimental tools. All mutant mice and the corresponding WT controls received three different doses (1, 5, and 15 mg/kg, s.c.) of the nonselective muscarinic agonist pilocarpine.
Studies with M 1 and M 3 receptor single-KO mice showed that the magnitudes of the observed salivation responses were critically dependent on the administered pilocarpine dose. The salivation response to the lowest dose of pilocarpine (1 mg/kg) was drastically reduced (by ϳ90%), but not abolished, in M 3 receptor single-KO mice (Fig. 1A) . A similar effect was observed when M 3 receptor single-KO mice were treated with another muscarinic agonist, oxotremorine (0.3 mg/kg, s.c.) (Bymaster et al., 2003) . In contrast, Matsui et al. (2000) reported that pilocarpine (1 mg/kg, s.c.)-mediated salivary secretion was completely abolished in M 3 receptor single-KO mice. A possible reason for the discrepancy between this and our study may be that Matsui et al. (2000) used a different method to measure salivary flow and employed mice of a somewhat different genetic background. It should also be noted that we found previously that 1 mg/kg (s.c.) of pilocarpine had little sialagogue activity (Ͻ2 mg saliva/g measured over a 30-min observation period) in either WT or M 3 receptor KO mice ). Possible explanations for the relatively low pilocarpine sensitivity of the mice used in this previous study may include differences in mouse age (present study, 10 weeks; previous study, 24 weeks) or mouse genetic background (present study, 129SvEv ϫ CF1; previous study, 129SvEV ϫ C57BL/6J). In any case, our present results are consistent with the concept that the M 3 receptor plays a key role in mediating cholinergic stimulation of salivary secretion (Laniyonu et al., 1990; Dai et al., 1991; Caulfield, 1993; Watson et al., 1996; Moriya et al., 1999; Matsui et al., 2000; Bockman et al., 2001; Bymaster et al., 2003) .
It is interesting that administration of the lowest dose of pilocarpine (1 mg/kg) also resulted in a significant reduction (by ϳ50%) in salivary output in M 1 receptor single-KO mice (Fig. 1A) , indicating that M 1 receptor activation also contributes to cholinergic stimulation of salivary flow. Likewise, Bymaster et al. (2003) recently reported that oxotremorine (0.3 mg/kg, s.c.) also showed significantly reduced sialagogue activity in M 1 receptor KO mice (reduction in saliva output by ϳ35% measured over a 15-min observation period). Pharmacological and biochemical techniques have also shown that M 1 receptors (as well as M 3 receptors) mediate stimulation of mucous acinar exocrine secretion in rat sublingual glands (Culp et al., 1996; Luo et al., 2001) .
In contrast with the lowest pilocarpine dose used (1 mg/kg, s.c.), the intermediate pilocarpine dose employed (5 mg/kg, s.c.) produced only a modest reduction (by ϳ20%) in salivary flow in the M 1 and M 3 receptor KO mice, which proved to be statistically significant only in the case of the M 3 receptor KO mice (Fig. 1B) . Finally, the highest pilocarpine dose used (15 mg/kg, s.c.) induced WT-like salivation responses in both M 1 and M 3 receptor single-KO mice (Fig. 1C) , indicating that the presence of either M 1 or M 3 receptors is sufficient to mediate robust salivary output. Consistent with this concept, pilocarpine (15 mg/kg, s.c.) induced the flow of similar amounts of saliva in M 1 /M 4 , M 2 /M 3 , and M 2 /M 4 receptor double-KO mice, compared with their corresponding WT control mice (Fig. 7) . The observation that a high dose of a muscarinic agonist can induce a maximum secretion response in both the M 1 and M 3 receptor KO mice can be explained best by assuming that M 1 and M 3 receptors are coexpressed by the saliva-producing acinar cells. If M 1 and M 3 receptors were expressed by different subpopulations of acinar cells, one would expect to observe reduced salivation responses in both the M 1 and M 3 receptor single-KO mice, even at maximum agonist doses.
Quantitative real-time RT-PCR experiments (TaqMan) showed that genetic inactivation of the M 1 or M 3 mAChR genes had no significant effect on the mRNA levels of the remaining mAChR subtypes in salivary gland tissues (Fig.  2) . It is therefore unlikely that the robust salivation responses observed in the M 1 and M 3 receptor single-KO mice after the administration of high doses of pilocarpine are caused by the compensatory overexpression of other mAChR subtypes. However, we cannot completely rule out minor changes in receptor protein expression levels or changes in receptor coupling properties that may occur despite unchanged receptor expression levels.
As discussed above, the pattern of salivation responses obtained with the lowest pilocarpine dose used (1 mg/kg) indicates that the M 3 receptor plays a key role in mediating stimulation of salivary flow in vivo, consistent with previous studies (Laniyonu et al., 1990; Dai et al., 1991; Caulfield, 1993; Watson et al., 1996; Moriya et al., 1999; Matsui et al., 2000; Bockman et al., 2001; Bymaster et al., 2003) . The predominant functional role of M 3 receptors in stimulating salivary secretion (at least at low agonist concentrations) is most probably a consequence of the preferential expression of M 3 receptors in salivary gland tissue. In the present study, [ 3 H]NMS binding studies indicated that ϳ65% of the mAChRs present in submandibular gland tissue are M 3 receptors, ϳ25% are M 1 receptors, and Ͻ10% represent other mAChR subtypes (Fig. 6 ). Quantitative RT-PCR studies indicated that the small population of non-M 1 /M 3 mAChRs probably represents a mixture of M 2 , M 4 , and M 5 receptors (Fig. 2) . It should also be noted in this context that immunoprecipitation studies have shown that rat sublingual gland tissue expresses approximately similar numbers of M 1 and M 3 receptors (Watson and Culp, 1994) . Moreover, radioligand binding studies suggest that human salivary gland tissues also express a mixture of M 1 and M 3 mAChRs (Giraldo et al., 1988; Mei et al., 1990) .
On the other hand, radioligand binding (Hammer et al., 1980; Dai et al., 1991; Bockman et al., 2001) , functional (Dai et al., 1991; Bockman et al., 2001) , and immunoprecipitation studies (Dai et al., 1991) indicate that the rat parotid gland almost exclusively expresses M 3 receptors. The contribution of M 1 receptors to muscarinic agonist (acetylcholine)-mediated stimulation of salivary secretion (see below) may therefore be mediated predominantly by M 1 receptors present in the submandibular and sublingual glands.
Several recent studies suggest that non-M 1 /M 3 mAChRs may also play a role in cholinergic stimulation of glandular secretion. For example, it has been proposed based on studies using subtype-preferring muscarinic antagonists that M 5 receptors may be present/functional in salivary gland tissue (Flynn et al., 1997; Meloy et al., 2001; Tobin et al., 2002) . Moreover, Takeuchi et al. (2002) reported that salivary secretion induced by pilocarpine (1 mg/kg, s.c.) was slightly reduced (by ϳ10 -20%) in M 5 receptor KO mice. Finally, Bymaster et al. (2003) recently found that administration of a single dose of oxotremorine (0.3 mg/kg, s.c.) resulted in a reduced salivation response in M 4 receptor single-KO mice (reduction in saliva output by ϳ35% measured over a 15-min observation period).
To test the hypothesis that non-M 1 /M 3 mAChRs play a significant role in cholinergic stimulation of salivary secretion in vivo, we generated and analyzed mice in which both the M 1 and M 3 receptor genes had been inactivated (M 1 /M 3 receptor double-KO mice). It was remarkable that pilocarpine, at any of the three doses tested, was no longer able to stimulate salivary secretion in M 1 /M 3 receptor double-KO mice (Fig. 3) . However, the ␤-adrenergic receptor agonist (S)-isoproterenol (1 mg/kg, s.c.) retained the ability to stimulate saliva production in M 1 /M 3 receptor double-KO mice with high efficacy (Fig. 4) , indicating that the functional deficits displayed by the M 1 /M 3 receptor double-KO mice were receptor-specific and not caused by changes in the expression levels of downstream signaling components. Our observation that pilocarpine-mediated stimulation of salivary flow in vivo is abolished in the M 1 /M 3 receptor double-KO mice indicates that non-M 1 /M 3 receptors, such as M 4 and M 5 receptors, are unlikely to make a significant contribution to muscarinic agonist-induced saliva production. The functional deficits displayed by the M 4 (Bymaster et al., 2003) and M 5 receptor single-KO mice are therefore most probably caused by other factors, such as mouse genetic background or altered expression levels of other signaling proteins. Takakura et al. (2003) recently showed that pilocarpine, which readily enters the brain, can stimulate salivary secretion by activating central mAChRs, probably by increasing parasympathetic outflow. Because the M 4 and M 5 mAChRs are preferentially expressed in the CNS (Wess, 1996; Caulfield and Birdsall, 1998) , the reduction in pilocarpine-or oxotremorine-induced stimulation of salivary function observed in M 4 (Bymaster et al., 2003) and M 5 mAChR KO mice could therefore also be caused by the lack of neuronal rather than glandular M 4 or M 5 receptors.
Although our data suggest that drugs devoid of activity at M 1 and M 3 receptors should lack adverse effects on salivation, clinical studies indicate that relative potency at M 3 mAChRs may not be a reliable predictor of xerostomia. For example, administration of the muscarinic antagonist solifenacin, which is endowed with a moderate degree of M 3 receptor selectivity, seems to cause less pronounced drymouth symptoms than tolterodine (nonselective) or darifenacin, another M 3 receptor-preferring antagonist (Ikeda et al., 2002; Chapple et al., 2004a,b; Kobayashi et al., 2004) . These differences in drug effects on salivary gland function observed in clinical studies may be caused by differences in pharmacokinetics, drug stability, or other as-yet-unknown parameters that affect drug activity at salivary glands in vivo.
In conclusion, our results indicate that muscarinic agonists trigger salivary secretion in vivo by activating a mixture of glandular M 1 and M 3 mAChRs. Other glandular mAChR subtypes are unlikely to be involved in mediating this activity, at least not in the mouse. These findings should be highly relevant for the development of novel, clinically useful muscarinic drugs.
